Challenges & Opportunities For Neoantigen Cell-Based Therapy
Tuesday 20 April - 10.00am - 15.00pm CEST
This focus day aims to delve deep into the promise, the progress and the pitfalls related to weaponising
neoantigen cell-based immunotherapies.
Much of the neoantigen field is dominated by efforts towards personalised vaccines; this session is solely focused on the challenges and opportunities related to neoantigen cell-based therapy.
10:00 am Chairs Opening Remarks
- Setting the scene: Why choose personalised cell therapy over personalised vaccines?
- Quick introduction as to why neoantigen cell therapy is behind neoantigen vaccine development in terms of number of active clinical trials
- Why pioneers in this space believe that cell therapy will soon surpass vaccines
10:10 am Novel Strategies to Improve Personalized Neoantigen Discovery
- Alena Gros Principal Investigator, Tumor Immunology & Immunotherapy, Vall d’Hebron Institute of Oncology (V.H.I.O)
- Development of novel personalized T cell therapies for cancer treatment
- Optimizing neoantigen discovery: novel strategy to preselect candidate neoantigens; comparison of tandem minigene screens and peptide pool screens for neoantigen identification
- Identification of tumor-infiltrating and peripheral blood T cell subsets enriched for neoantigen recognition
10:40 am Delving into the Properties of T-Cell Recognized Neoantigens
- Pia Kvistborg Junior group leader, Department of Immunology , The Netherlands Cancer Institute
- Leveraging an in-silico prediction pipeline
- Identifying T cell recognized neoantigens
- Elucidating properties that may lead to T cell recognition
- How can we use this platform to help predict immunogenicity
11:10 am Morning Refreshments & Speed Networking
11:40 am Leveraging the experience from development of individualized cancer vaccines to vaccines against infectious diseases, including pandemics using the Vaccibody platform technology
- Agnete Fredriksen President & Chief Scientific Officer, Vaccibody
Targeting antigens to antigen presenting cells to generate more rapid, strong, broad and long-lasting responses
Transferability of manufacturing considerations
Weighing the importance of humoral versus cellular responses, including choice of antigens
12:10 pm Computational Design of a Global Peptide-based COVID-19 vaccine for Variable Viral Strains and Variable Human Genetics
- Eniko R Toke Chief Scientific Officer, Treos Bio
• Validated strategy to optimize vaccines for individuals and populations instead of distinct HLA alleles, using in silico clinical
trials of real subjects
• Safety and immunogenicity of PolyPEPI-SCoV-2 in 2 mouse models
• How a cocktail of 9 peptides mimics the diversity of T cell responses induced by natural SARS-CoV-2 infection
• Extrapolation of findings in COVID-19 convalescent subjects to 16,000 HLA-genotyped subjects with 16 different ethnicities
12.50 pm Lunch
1:50 pm Building on Experience: A T cell epitope-driven COVID-19 Vaccine using the iVAX Platform
- Anne De Groot CEO/ CSO, EpiVax, Inc
• Fast, safe, and effective: T cell epitope driven vaccines
• Power of iVAX toolkit and Rationale for pivot to COVID-19
• Current Plans for safety and immunogenicity studies
2:20 pm FLOVID-20: A Targeted T-cell Immunotherapy for COVID-19 using a Nebulizer
- Scott Burkholz Bioinformatics Scientist , Flow Pharma, Inc.
Microsphere technology encapsulates peptides and adjuvant for inhaled delivery to stimulate the immune system towards SARS-CoV-2.
Non-human primates vaccinated via inhalation were shown to have an immune response towards SARS-CoV-2 nucleoprotein, leading to protection against COVID-19.
2:50 pm Designing Best in Class TCR Cell Therapies Against Novel Antigens
- Hans-Peter Gerber CEO & CSO, 3T Biosciences
- Identifying the nuances of neoantigen TCR-based therapies to allow acceleration to the clinic
- Importance of diversity for identifying first in class targets and best in class T cell receptors while minimizing off-target toxicity
- Characterizing T cell receptors with the ideal binding profile.
- Utilization of a mass spectrometry independent yeast display platform that leverages in silico based prediction models to de-risk T cell receptor cell therapies.
3:20 pm Engineered T cells for the Treatment of Malignancy
- Jennie Lill Executive Director of Proteomics & NGS, Genentech
- Challenges with current therapeutic modalities, and why engineered T cell therapeutics are an attractive option.
- Challenges and improvements to in silico based prediction methods for selecting epitopes for generating TCRs against.
- Current strategy for selecting epitopes for engineering T cells against using a combination of biochemical and mass spectrometric approaches.